Michal Vrablik (Michal Vrablík)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 7

Top Topics

Drug Administration

Left Ventricular

Cardiovascular Disease

Top Venues

Pharmaceuticals (Basel, Switzerland)

Current atherosclerosis reports

Rheumatology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Michal Vrablik, Ivana Šarkanová, Katarína Breciková, Petra Sedova, Martin Šatný, Aleš Tichopád
Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias. PloS one 18 (5) (2023)
Niki Katsiki, Michal Vrablik, Maciej Banach, Ioanna Gouni-Berthold
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Niki Katsiki, Michal Vrablik, Maciej Banach, Ioanna Gouni-Berthold
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Niki Katsiki, Michal Vrablik, Maciej Banach, Ioanna Gouni-Berthold
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Niki Katsiki, Michal Vrablik, Maciej Banach, Ioanna Gouni-Berthold
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Sabína Oreská, Hana Storkanova, Jaroslav Kudlicka, Vladimir Tuka, Ondrej Mikes, Zdislava Krupickova, Martin Satny, Eva Chytilova, Jan Kvasnicka, Maja Špiritović, Barbora Heřmánková, Petr Česák, Marian Rybar, Karel Pavelka, Ladislav Senolt, Heřman Mann, Jiri Vencovsky, Michal Vrablik, Michal Tomcik
Cardiovascular risk in myositis patients compared to the general population. Rheumatology (Oxford, England) (2023)
Martin Satny, Jaroslav A Hubacek, Michal Vrablik
Statins and Inflammation. Current atherosclerosis reports 23 (12) (2021)